A team of researchers have created a method of measuring how circulating tumor cells perform functions that drive cancer, such as producing matrix metalloproteases.
Browsing: prostate cancer
Among prostate cancer patients, those with DNA mismatch repair mutations have particularly aggressive progression and reduced survivability. Though these tumors are more resistant to traditional treatment methods, a recent study has shown that they may be more susceptible to immunotherapy.
A gene that’s associated with an autoimmune form of hair loss could be exploited to improve cancer immunotherapy, suggests a new mouse study.
Researchers have developed a quicker and more accurate way of testing new prostate cancer treatments.
A test that is able to detect trace levels of circulating tumor cells could help spot the early signs of treatment not working for advanced prostate cancer patients.
Researchers have uncovered a key mechanism that drives hormone therapy resistance in prostate cancer.
Genetic test could identify prostate cancer patients who are most likely to benefit from immunotherapy
A genetic test could aid the identification of men with prostate cancer who are most likely to benefit from immunotherapy.
The prostate cancer test combines genetic variations linked to prostate cancer and identifies the 1% of men that are at high risk.
ASCO18: Prostate cancer survival in black men following chemotherapy may be as good, or better, as in white men
Analysis of data from more than 8000 men with advanced prostate cancer who received chemotherapy suggests survival chances for black men are at least as good as those for white men when provided with equal treatment.
A prospective clinical trial, involving 100 men with metastatic castration-resistant prostate cancer, has demonstrated that black men experience a greater and longer lasting response to the hormone treatment abiraterone compared with white men.